Short Interest in Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Drops By 37.4%

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) saw a large decline in short interest in December. As of December 31st, there was short interest totaling 6,009 shares, a decline of 37.4% from the December 15th total of 9,599 shares. Based on an average daily volume of 2,678 shares, the days-to-cover ratio is presently 2.2 days. Currently, 0.6% of the shares of the company are short sold. Currently, 0.6% of the shares of the company are short sold. Based on an average daily volume of 2,678 shares, the days-to-cover ratio is presently 2.2 days.

Addex Therapeutics Stock Performance

Addex Therapeutics stock opened at $7.98 on Friday. Addex Therapeutics has a fifty-two week low of $6.51 and a fifty-two week high of $12.05. The firm has a market capitalization of $9.82 million, a price-to-earnings ratio of -1.39 and a beta of 1.49. The stock’s fifty day moving average is $8.06 and its two-hundred day moving average is $8.52.

Addex Therapeutics (NASDAQ:ADXN) last released its quarterly earnings results on Thursday, December 4th. The company reported ($1.51) earnings per share (EPS) for the quarter. The firm had revenue of $0.04 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Addex Therapeutics in a report on Friday, January 9th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

About Addex Therapeutics

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.